Effect of Alternate Treatment with Intravitreal Anti-Vascular Endothelial Growth Factor and Corticosteroid for Macular Edema

Not Applicable

• Conditions: Diseases of the eye and adnexa

• Registration Number: KCT0007766
• Lead Sponsor: Hallym University Medical Center-Kangnam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 October 2022

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 188

Inclusion Criteria

CRT = 300 um due to DME or ME secondary to RVO at the time of screening.
- Best corrected visual acuity (BCVA) 20/32~20/200 at the time of screening .

Exclusion Criteria

Excluded if any of the following criteria are met
- If there is a history of intravitreal anti-VEGF or corticosteroid injection within 3 months of screening.
- In case of receiving systemic anti-VEGF or corticosteroid treatment within 3 months of screening.
- In the case of receiving panretinal photocoagulation treatment within 3 months of screening.
- In the case of receiving corticosteroid eye drop treatment within 3 months of screening.
- If there is a history of idiopathic or autoimmune uveitis in the trial or the disease is confirmed at the time of screening.
- If you have had intraocular surgery except for simple cataract surgery.
- If there is a history of glaucoma in the trial or the disease is confirmed at the time of screening.
- If there is a history of retinal diseases other than diabetic retinopathy and retinal vein occlusion in the trial, or the disease is confirmed at the time of screening.

Study & Design

• Study Type: Interventional Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mean change of BCVA from the baseline

Secondary Outcome Measures

Name	Time	Method
Mean change of BCVA from the baseline;Mean change of CRT from the baseline;Mean change of CRT from the baseline;Change of aqueous humor cytokine level from the baseline;Change of aqueous humor cytokine level from the baseline;Proportion of subjects with an absence of intraretinal or subretinal fluid;Proportion of subjects with an absence of intraretinal or subretinal fluid;Number of intravitreal injections performed during the treatment period (12 months)